Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients

This study conducted a pairwise comparison of antihypertensive and metabolic effects of hydrochlorothiazide (HCTZ) and chlorthalidone (CTD) at 25 mg/day in the same individuals to address the clinical dilemma on preferred thiazide for hypertension (HTN) management. We included 15 African American (A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and translational science 2022-12, Vol.15 (12), p.2858-2867
Hauptverfasser:	Chekka, Lakshmi Manasa S., Cooper‐DeHoff, Rhonda M., Gums, John G., Chapman, Arlene B., Johnson, Julie A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antihypertensive Agents - adverse effects Antihypertensives Blood Pressure Chlorthalidone - adverse effects Clinical trials Diuretics Drug dosages Drug Therapy, Combination Humans Hydrochlorothiazide Hydrochlorothiazide - adverse effects Hypertension Hypertension - drug therapy Hypokalemia Hypokalemia - chemically induced Hypokalemia - drug therapy Metabolism Metabolites Pharmacogenomics Population Potassium Principal components analysis Supplements Thiazides Thiazides - pharmacology Thiazides - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This study conducted a pairwise comparison of antihypertensive and metabolic effects of hydrochlorothiazide (HCTZ) and chlorthalidone (CTD) at 25 mg/day in the same individuals to address the clinical dilemma on preferred thiazide for hypertension (HTN) management. We included 15 African American (AA) and 35 European American (EA) patients with HTN treated with HCTZ and CTD as part of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and PEAR‐2 trials, respectively. Mean reduction in systolic/diastolic blood pressure (SBP/DBP) with HCTZ versus CTD was 8/5 versus 16/8 mmHg among EA patients (p
ISSN:	1752-8054 1752-8062
DOI:	10.1111/cts.13396